Table 1: Demographics, clinicopathologic, and treatment characteristics.

All patients Patients without recurrence Patients with recurrence -value
No. (%)No. (%)No. (%)

Age
 Mean (SD)54.79 (11.52)55.93 (14.90)52.58 (13.18)0.19
 Median555653
Histology0.95*
 IDC76 (83.51)50 (83.33) 26 (83.87)
 ILC13 (14.28) 8 (13.33) 5 (16.13)
 Other2 (2.2) 2 (3.33) 0 (0.00)
Grade0.56*
 Grade 118 (19.78)14 (23.33)4 (12.90)
 Grade 229 (31.87)19 (31.76)10 (32.26)
 Grade 331 (34.06) 18 (30.00) 13 (48.15)
 Unknown13 (14.29) 9 (15.00)4 (12.90)
Tumor stage0.42*
 T152 (57.14) 37 (61.66) 15 (48.39)
 T228 (30.76)16 (26.66) 12 (38.71)
 T3-410 (10.98) 6 (10.00) 4 (12.90)
 Unknown1 (0.11) 1 (1.66) 0 (0.00)
Nodal Stage0.02*
 N056 (61.53) 40 (66.66)16 (51.61)
 N119 (20.87) 14 (23.33) 5 (16.13)
 N2-315 (16.48) 5 (8.33) 10 (32.26)
 Unknown1 (0.11) 1 (1.66) 0 (0.00)
AJCC Stage0.02
 I42 (46.15) 32 (53.33) 10 (32.26)
 II31 (34.06)21 (35.00) 10 (32.26)
 III18 (19.78)7 (11.66) 11 (35.48)
Hormone receptor status0.09*
 ER and PR negative24 (26.37) 12 (20.00) 12 (38.71)
 ER and/or PR positive65 (71.42) 46 (76.66) 19 (61.29)
 Unknown2 (2.19) 2 (3.33) 0 (0.00)
HER2/neu status0.62*
 Negative73 (80.22)50 (83.33)23 (74.19)
 Positive13 (14.28) 8 (13.33) 5 (16.13)
 Unknown5 (5.49) 2 (3.33) 3 (9.68)
Adjuvant chemotherapy0.85
 Yes62 (68.1) 40 (66.66) 22 (70.96)
 No29 (31.9) 20 (33.33) 9 (29.03)
Adjuvant endocrine therapy<0.01
 Yes63 (69.2) 47 (78.33) 16 (51.61)
 No28 (30.8) 13 (21.66) 15 (48.38)
Adjuvant radiotherapy0.3
 Yes73 (80.2) 50 (83.33) 23 (74.19)
 No18 (19.8) 10 (16.66) 8 (25.81)

SD: standard deviation; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma.
Excluding “unknown” or “other” category.